Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics will present primary results from the pivotal Phase 3 ACACIA-HCM trial of aficamten in non-obstructive hypertrophic cardiomyopathy at the ESC Congress 2026. The data, described as positive topline results, will be featured in a Hot Line presentation on August 28, alongside two additional late-breaking science abstracts on cardiac structure and comparative efficacy.
Key figures
- Drug Name
- aficamten
- Phase Of Trial
- Phase 3
- Indication
- non-obstructive hypertrophic cardiomyopathy (nHCM)
- Trial name
- ACACIA-HCM
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.